Private Ryan
Established Member
- Reaction score
- 2
http://content.karger.com/ProdukteDB/pr ... =92842.pdf
The Efficacy of 5% Minoxidil vs. Combined Topical Agent of 5% Minoxidil and 0.01% Tretinoin on Male Pattern Hair Loss:
A Randomised Comparative Clinical Trial
H.-S. Shin Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea
Topical minoxidil 5% solution has been widely used to stimulate new hair growth and to help stop the hair loss successfully in men
with male pattern hair loss (MPHL). Nevertheless, it is not easy for the patients to keep applying the solution twice a day regularly.
The purpose of this 18-week, double-blind, randomised study was to compare the efficacy and safety of the treatment of combined solution
of 5% minoxidil and 0.01% tretinoin once a day with conventional topical 5% minoxidil therapy applied twice a day in the treatment of
MPHL.
A total of 29 male patients (25–50 years old) with MPHL (Hamilton type III–V) were randomly assigned to apply 5% minoxidil
twice daily or the combined agent once a day at night using vehicle placebo in the morning. The efficacy parameters were (1) changes
in total hair count, mean hair thickness and linear growth rate measured by phototrichogram and (2) the patient and investigator subjective
assessment of change in scalp coverage.
After 18-weeks of therapy, significant increases in the all macrophotographic variables of total hair count, mean hair diameter and linear growth rate were shown in both treatment groups. Moreover, the 5% minoxidil and the combined agent groups also demonstrated similar improvement in the subjective global assessment by patient and investigator
There was no statistically significant difference between the treatment groups. The occurrence of side effects like pruritus or local irritation was similar in 5% minoxidil group (5 of 14 subjects) and the combined agent group (5 of 15 subjects).
In conclusion, the efficacy and safety of combined 5% minoxidil and 0.01% tretinoin once-daily treatment would be equivalent to the conventional 5% minoxidil twice-a-day therapy for treatment of MPHL.
The Efficacy of 5% Minoxidil vs. Combined Topical Agent of 5% Minoxidil and 0.01% Tretinoin on Male Pattern Hair Loss:
A Randomised Comparative Clinical Trial
H.-S. Shin Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea
Topical minoxidil 5% solution has been widely used to stimulate new hair growth and to help stop the hair loss successfully in men
with male pattern hair loss (MPHL). Nevertheless, it is not easy for the patients to keep applying the solution twice a day regularly.
The purpose of this 18-week, double-blind, randomised study was to compare the efficacy and safety of the treatment of combined solution
of 5% minoxidil and 0.01% tretinoin once a day with conventional topical 5% minoxidil therapy applied twice a day in the treatment of
MPHL.
A total of 29 male patients (25–50 years old) with MPHL (Hamilton type III–V) were randomly assigned to apply 5% minoxidil
twice daily or the combined agent once a day at night using vehicle placebo in the morning. The efficacy parameters were (1) changes
in total hair count, mean hair thickness and linear growth rate measured by phototrichogram and (2) the patient and investigator subjective
assessment of change in scalp coverage.
After 18-weeks of therapy, significant increases in the all macrophotographic variables of total hair count, mean hair diameter and linear growth rate were shown in both treatment groups. Moreover, the 5% minoxidil and the combined agent groups also demonstrated similar improvement in the subjective global assessment by patient and investigator
There was no statistically significant difference between the treatment groups. The occurrence of side effects like pruritus or local irritation was similar in 5% minoxidil group (5 of 14 subjects) and the combined agent group (5 of 15 subjects).
In conclusion, the efficacy and safety of combined 5% minoxidil and 0.01% tretinoin once-daily treatment would be equivalent to the conventional 5% minoxidil twice-a-day therapy for treatment of MPHL.